Shattuck Labs Initiated RECEPTIVE-CD1 Phase 2b Trial Of SL-325 In Crohn’s Disease, 12-Week Induction Data Expected In H1 2028; Expects To Start Phase 2 In Hidradenitis Suppurativa In Q4 2026

Loading news article.

Shattuck Labs Initiated RECEPTIVE-CD1 Phase 2b Trial Of SL-325 In Crohn’s Disease, 12-Week Induction Data Expected In H1 2028; Expects To Start Phase 2 In Hidradenitis Suppurativa In Q4 2026 | WAPE

Shattuck Labs Initiated RECEPTIVE-CD1 Phase 2b Trial Of SL-325 In Crohn’s Disease, 12-Week Induction Data Expected In H1 2028; Expects To Start Phase 2 In Hidradenitis Suppurativa In Q4 2026

Article summary

Related companies

Analyzed by WAPE AI.

Comments —